meta
|
Preg
- medecines during pregnancy KB
Search
Carbimazole, Thiamazole (Methimazole)
Overall results
Study description
Excluded studies
Table
Graphic
auto
during pregnancy (anytime or not specified)
1st trimester
2nd trimester
3rd trimester
2nd and/or 3rd trimester
throughout pregnancy
early pregnancy
days before delivery
late pregnancy
preconception-only
periconceptional
preconceptional for kinetic reason
at least 1st trimester
3 months (or more) before pregnancy or during pregnancy
1st and 2nd trimester
3 months or more before pregnancy or1st trimester
Whatever the period exposition
individual studies
Outcome
TE
95% CI
n cases
n exposed
k
Pub. bias
Congenital malformations
All congenital malformations (majors, minors, majors and minors, or unspecified)
Momotani, 1984 Wing (control unexposed, sick), 1994 Dwarakanath (control exposed to PTU), 1999 Di Gianantonio, 2001 Azizi, 2002 Banhidy, 2011 Yoshihara (control unexposed, sick), 2012 Gianetti (control unexposed, sick), 2015 Hawken (control exposed to PTU), 2016 Andersen 2017 (control unexposed, sick), 2017 Seo (control unexposed, NOS), 2018 Andersen (control unexposed, disease free), 2019 Yoshihara (Controls unexposed, sick), 2021
13
1.40
[
1.14
; 1.72]
249,132
4,773
low
Major congenital malformations
Momotani, 1984 Wing (control unexposed, sick), 1994 Dwarakanath (control exposed to PTU), 1999 Di Gianantonio, 2001 Banhidy, 2011 Yoshihara (control unexposed, sick), 2012 Gianetti (control unexposed, sick), 2015
7
1.78
[
1.18
; 2.69]
205
1,852
serious
Genital anomalies
Andersen 2017 (control unexposed, sick), 2017 Seo (control unexposed, NOS), 2018 Andersen (control unexposed, disease free), 2019
3
1.11
[
0.75
; 1.63]
25,766
2,856
not evaluable
Limb defects
Andersen 2017 (control unexposed, sick), 2017 Seo (control unexposed, NOS), 2018 Andersen (control unexposed, disease free), 2019
3
0.85
[
0.65
; 1.12]
74,533
2,856
not evaluable
Respiratory system anomalies
Andersen 2017 (control unexposed, sick), 2017 Seo (control unexposed, NOS), 2018 Andersen (control unexposed, disease free), 2019
3
1.62
[
1.11
; 2.37]
15,998
2,856
not evaluable
Urinary malformations
Andersen 2017 (control unexposed, sick), 2017 Seo (control unexposed, NOS), 2018 Andersen (control unexposed, disease free), 2019
3
1.69
[
1.08
; 2.67]
17,645
2,856
not evaluable
Carbimazole embryopathy
Di Gianantonio, 2001 Barbero, 2008 Clementi, 2010 Yoshihara (control unexposed, sick), 2012 Seo (control unexposed, NOS), 2018 Andersen (control unexposed, disease free), 2019
6
14.62
[
10.40
; 20.55]
2,316
4,301
not evaluable
Eye defects
Andersen 2017 (control unexposed, sick), 2017 Andersen (control unexposed, disease free), 2019
2
2.38
[
1.21
; 4.71]
2,493
1,736
not evaluable
Congenital heart defects
Andersen 2017 (control unexposed, sick), 2017 Seo (control unexposed, NOS), 2018 Andersen (control unexposed, disease free), 2019
3
1.73
[
1.40
; 2.15]
77,405
2,856
not evaluable
Digestive system anomalies
Andersen 2017 (control unexposed, sick), 2017 Seo (control unexposed, NOS), 2018 Andersen (control unexposed, disease free), 2019
3
2.99
[
2.05
; 4.36]
15,273
2,856
not evaluable
Severe congenital heart defect
Clementi, 2010 Yoshihara (control unexposed, sick), 2012
2
0.87
[
0.25
; 3.03]
739
1,311
not evaluable
Abdominal wall defects
Andersen 2017 (control unexposed, sick), 2017 Andersen (control unexposed, disease free), 2019
2
5.44
[
2.63
; 11.23]
933
1,736
not evaluable
Ear, face and neck anomalies
Andersen 2017 (control unexposed, sick), 2017 Andersen (control unexposed, disease free), 2019
2
0.58
[
0.08
; 4.33]
912
1,736
not evaluable
Nervous system anomalies
Andersen 2017 (control unexposed, sick), 2017 Seo (control unexposed, NOS), 2018
2
2.85
[
1.39
; 5.87]
5,852
1,282
not evaluable
Omphalocele
Clementi, 2010 Yoshihara (control unexposed, sick), 2012 Yoshihara (Controls unexposed, sick), 2021
3
9.70
[
3.27
; 28.78]
163
1,334
not evaluable
Syndromes and chromosomal abnormalities
Andersen 2017 (control unexposed, sick), 2017 Andersen (control unexposed, disease free), 2019
2
1.16
[
0.62
; 2.17]
5,553
1,736
not evaluable
Ano-rectal atresia and stenosis
Yoshihara (control unexposed, sick), 2012 Yoshihara (Controls unexposed, sick), 2021
2
1.77
[
0.22
; 14.34]
4
1,254
not evaluable
Atresia of bile ducts
Yoshihara (control unexposed, sick), 2012 Yoshihara (Controls unexposed, sick), 2021
2
2.94
[
0.36
; 24.10]
3
1,254
not evaluable
Cardiac septal defects
Andersen 2014 (control unexposed, disease free), 2014
1
1.87
[
1.14
; 3.06]
-
1,097
not evaluable
Congenital hydronephrosis
Yoshihara (control unexposed, sick), 2012 Yoshihara (Controls unexposed, sick), 2021
2
4.41
[
0.48
; 40.36]
3
1,254
not evaluable
Hypospadias
Yoshihara (control unexposed, sick), 2012 Yoshihara (Controls unexposed, sick), 2021
2
3.81
[
0.32
; 46.05]
1
1,254
not evaluable
Oro-facial clefts
Seo (control unexposed, NOS), 2018 Yoshihara (Controls unexposed, sick), 2021
2
1.54
[
0.19
; 12.70]
3,448
1,143
not evaluable
Other congenital malformations (Q80-84)
Andersen 2017 (control unexposed, sick), 2017 Andersen (control unexposed, disease free), 2019
2
2.32
[
0.38
; 14.27]
2,022
1,736
not evaluable
Ventricular septal defect
Yoshihara (control unexposed, sick), 2012 Yoshihara (Controls unexposed, sick), 2021
2
1.31
[
0.56
; 3.06]
25
1,254
not evaluable
Ear malformations
Andersen 2017 (control unexposed, sick), 2017
1
9.60
[
0.19
; 485.50]
-
162
not evaluable
Situs inversus
Clementi, 2010 Yoshihara (control unexposed, sick), 2012
2
5.49
[
0.58
; 51.80]
25
1,311
not evaluable
Aortic valve atresia/stenosis
Yoshihara (control unexposed, sick), 2012
1
0.52
[
0.02
; 12.68]
1
1,231
not evaluable
Aplasia cutis congenita
Yoshihara (control unexposed, sick), 2012
1
23.36
[
1.33
; 409.42]
7
1,231
not evaluable
Atresia or stenosis of other parts of small intestine
Yoshihara (control unexposed, sick), 2012
1
4.65
[
0.19
; 114.23]
1
1,231
not evaluable
Atrial septal defect
Yoshihara (control unexposed, sick), 2012
1
0.52
[
0.02
; 12.68]
1
1,231
not evaluable
Brachydactyly
Yoshihara (control unexposed, sick), 2012
1
1.55
[
0.03
; 78.10]
-
1,231
not evaluable
Choanal atresia
Barbero, 2008 Clementi, 2010
2
25.89
[
7.52
; 89.13]
119
92
not evaluable
Chromosomal abnormalities
Gianetti (control unexposed, sick), 2015
1
0.32
[
0.02
; 6.82]
2
124
not evaluable
Cleft lip with or without cleft palate
Yoshihara (control unexposed, sick), 2012
1
0.31
[
0.01
; 6.45]
2
1,231
not evaluable
Club foot / Talipes equinovarus
Yoshihara (control unexposed, sick), 2012
1
0.52
[
0.02
; 12.68]
1
1,231
not evaluable
Congenital cataract
Yoshihara (control unexposed, sick), 2012
1
0.52
[
0.02
; 12.68]
1
1,231
not evaluable
Craniosynostosis
Yoshihara (control unexposed, sick), 2012
1
1.55
[
0.10
; 24.79]
2
1,231
not evaluable
Diaphragmatic hernia
Yoshihara (control unexposed, sick), 2012
1
0.52
[
0.02
; 12.68]
1
1,231
not evaluable
Down syndrom / Trisomy 21
Yoshihara (control unexposed, sick), 2012
1
2.33
[
0.39
; 13.94]
5
1,231
not evaluable
Eye, ear, face and neck malformations
Seo (control unexposed, NOS), 2018
1
1.00
[
0.37
; 2.69]
9,447
1,120
not evaluable
Intestinal malrotation
Yoshihara (control unexposed, sick), 2012
1
0.22
[
0.01
; 4.28]
3
1,231
not evaluable
Multicystic renal dysplasia
Yoshihara (control unexposed, sick), 2012
1
1.55
[
0.10
; 24.79]
2
1,231
not evaluable
Oesophageal atresia with or without tracheo-oesophageal fistula
Yoshihara (control unexposed, sick), 2012
1
7.76
[
0.37
; 161.69]
2
1,231
not evaluable
Other congenital malformations (Q80 to Q99)
Seo (control unexposed, NOS), 2018
1
1.91
[
0.95
; 3.83]
10,031
1,120
not evaluable
Patent ductus arterious
Yoshihara (control unexposed, sick), 2012
1
13.98
[
0.75
; 259.95]
4
1,231
not evaluable
Polydactyly
Yoshihara (Controls unexposed, sick), 2021
1
21.09
[
0.41
; 1087.34]
-
23
not evaluable
Pulmonary artery stenosis
Yoshihara (control unexposed, sick), 2012
1
0.52
[
0.02
; 12.68]
1
1,231
not evaluable
Pulmonary valve stenosis
Yoshihara (Controls unexposed, sick), 2021
1
7.01
[
0.28
; 177.06]
1
23
not evaluable
Spina bifida
Yoshihara (control unexposed, sick), 2012
1
4.65
[
0.19
; 114.23]
1
1,231
not evaluable
Sturge-Weber syndrome
Yoshihara (control unexposed, sick), 2012
1
4.65
[
0.19
; 114.23]
1
1,231
not evaluable
Syndactyly
Yoshihara (control unexposed, sick), 2012
1
0.52
[
0.02
; 12.68]
1
1,231
not evaluable
Tetralogy of Fallot
Yoshihara (control unexposed, sick), 2012
1
4.65
[
0.19
; 114.23]
1
1,231
not evaluable
Transposition of the great vessels
Yoshihara (control unexposed, sick), 2012
1
0.52
[
0.02
; 12.68]
1
1,231
not evaluable
Growth parameters and prematurity
Preterm (< 37 weeks)
Dwarakanath (control exposed to PTU), 1999 Azizi, 2002 Chen (control unexposed, sick), 2011 Gianetti (control unexposed, sick), 2015
4
1.21
[
0.65
; 2.23]
184
227
not evaluable
Low birth weight (< 2500g)
Dwarakanath (control exposed to PTU), 1999 Chen (control unexposed, sick), 2011
2
1.60
[
0.46
; 5.51]
141
80
not evaluable
Small for gestational age (weight)
Chen (control unexposed, sick), 2011
1
1.25
[
0.70
; 2.24]
381
73
not evaluable
Maternal consequences
Maternal liver disorder / failure during pregnancy
Lo (control exposed to PTU), 2015
1
2.35
[
0.10
; 58.31]
1
79
not evaluable
Caesarean
0
-
-
-
-
-
Gestational diabetes
Gianetti (control unexposed, sick), 2015
1
0.54
[
0.02
; 13.46]
1
124
not evaluable
Preeclampsia
Gianetti (control unexposed, sick), 2015
1
0.54
[
0.02
; 13.46]
1
124
not evaluable
Neonatal disorders
Goiter
Momotani (control exposed to PTU), 1997 Dwarakanath (control exposed to PTU), 1999 Hawken (control exposed to PTU), 2016
3
0.96
[
0.20
; 4.60]
6
61
not evaluable
Hearing loss / Auditory deficit
Yoshihara (control unexposed, sick), 2012 Yoshihara (Controls unexposed, sick), 2021
2
3.68
[
0.41
; 32.73]
4
1,254
not evaluable
Hypothyroidism (fetal/neonatal)
Wing (control unexposed, sick), 1994 Dwarakanath (control exposed to PTU), 1999 Hawken (control exposed to PTU), 2016
3
0.88
[
0.10
; 7.50]
1
54
not evaluable
Neonatal hyperthyrotropinemia
Momotani (control exposed to PTU), 1997
1
0.63
[
0.19
; 2.07]
13
43
not evaluable
Hyperthyroidism / Thyrotoxicosis (fetal/neonatal)
Dwarakanath (control exposed to PTU), 1999 Hawken (control exposed to PTU), 2016
2
0.77
[
0.06
; 9.94]
1
18
not evaluable
Intrauterine deaths
Elective/induced termination of pregnancy
Yoshihara (control unexposed, sick), 2012 Gianetti (control unexposed, sick), 2015
2
3.39
[
1.80
; 6.37]
46
1,550
not evaluable
Perinatal death
Yoshihara (control unexposed, sick), 2012 Gianetti (control unexposed, sick), 2015
2
0.70
[
0.25
; 1.94]
16
1,550
not evaluable
Early intrauterine death (< 22 weeks)
Di Gianantonio, 2001 Yoshihara (control unexposed, sick), 2012
2
3.94
[
0.70
; 22.25]
332
1,654
not evaluable
Intrauterine deaths (as a whole or unspecified)
Dwarakanath (control exposed to PTU), 1999 Gianetti (control unexposed, sick), 2015
2
1.97
[
0.89
; 4.35]
26
131
not evaluable
Neuro-developmental disorders
Neuro-developmental disorders (as a whole)
McCarroll (Buckinghamshire control group), 1976
1
5.34
[
2.17
; 13.10]
692
20
not evaluable
Language disorders/delay
Azizi, 2002
1
0.79
[
0.29
; 2.13]
-
23
not evaluable
0.0
100.0
1.0